PetVivo (PETV) Q4 2026 earnings summary

Executive summary

• Fiscal year 2026 featured rapid transformation, IP and product development, and platform commercialization, with a focus on high-margin, recurring revenue streams.

• Achieved Health Canada regulatory recognition for SpryngⓇ, enabling commercialization in Canada and expanding international opportunities.

• Strategic alliances included a 10-year exclusive licensing agreement with Digital Landia for AgenticPet AI technology and the acquisition of PiezoBioMembrane (PBM) to enhance biomaterial and regenerative product offerings.

• Launched AgenticPet B2C AI platform, onboarding 1,000+ beta users in 72 hours, and advanced B2B SaaS veterinary platform with significant reductions in customer acquisition costs.

• Expanded strategic partnerships, including with Veterinary Growth Partners and Commonwealth Markets, to drive adoption of SpryngⓇ and new AI solutions.

Financial highlights

• Fiscal 2026 revenues increased 1% year-over-year to $1.14 million, with distributor sales at $886,000 and direct clinic sales at $255,000.

• Gross profit was $754,751 (66.1% of revenues), down from $994,900 (87.8%) due to lower-margin PrecisePRP sales.

• Operating expenses rose to $9.82 million from $9.05 million year-over-year, driven by a $1 million impairment and higher sales/marketing costs.

• Net loss increased to $10.88 million ($0.38/share) from $8.4 million ($0.41/share) in the prior year.

• Cash and equivalents at year-end were $200,782, down from $227,689 the previous year.

Outlook and guidance

• Anticipates continued sales momentum and market penetration in fiscal 2027 and beyond, leveraging new product launches and expanded international opportunities.

• Expects commercial launch of PetVivo.ai SaaS platform and Spryng in Canada within months, targeting high-margin recurring revenue.

• Large animal studies with Powell Diazo and University of Connecticut expected to complete by year-end, providing key marketing data for veterinary and human markets.

• Plans to pursue FDA clearance for new products incorporating PBM technology.

• Sees strong growth potential in U.S. and Canadian animal health markets, with industry analysts projecting the U.S. market to double by 2030.